Balance Sheet
Cash Flow Statement
AcquisitionsCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesSales of Property, Plant and Equipment
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fresenius Medical Care AG (FMS) Exchange Rate Effect (2016 - 2025)

Historic Exchange Rate Effect for Fresenius Medical Care AG (FMS) over the last 17 years, with Q3 2025 value amounting to -$19.0 million.

  • Fresenius Medical Care AG's Exchange Rate Effect fell 3964.84% to -$19.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$68.3 million, marking a year-over-year decrease of 2960.08%. This contributed to the annual value of $28.0 million for FY2024, which is 13583.56% up from last year.
  • As of Q3 2025, Fresenius Medical Care AG's Exchange Rate Effect stood at -$19.0 million, which was down 3964.84% from -$80.0 million recorded in Q2 2025.
  • Over the past 5 years, Fresenius Medical Care AG's Exchange Rate Effect peaked at $60.1 million during Q3 2021, and registered a low of -$96.5 million during Q4 2022.
  • Over the past 5 years, Fresenius Medical Care AG's median Exchange Rate Effect value was -$4.9 million (recorded in 2024), while the average stood at -$2.1 million.
  • Its Exchange Rate Effect has fluctuated over the past 5 years, first surged by 102964.91% in 2021, then tumbled by 86197.0% in 2025.
  • Over the past 5 years, Fresenius Medical Care AG's Exchange Rate Effect (Quarter) stood at $35.6 million in 2021, then tumbled by 371.2% to -$96.5 million in 2022, then soared by 73.18% to -$25.9 million in 2023, then soared by 309.8% to $54.3 million in 2024, then crashed by 134.93% to -$19.0 million in 2025.
  • Its last three reported values are -$19.0 million in Q3 2025, -$80.0 million for Q2 2025, and -$23.6 million during Q1 2025.